IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v32y2014i4p395-409.html
   My bibliography  Save this article

Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines

Author

Listed:
  • Josephine Mauskopf
  • Miny Samuel
  • Doreen McBride
  • Usha Mallya
  • Steven Feldman

Abstract

Cost-effectiveness models of first-line biologics for moderate to severe plaque psoriasis either do not include subsequent treatment regimens or include only some of the regimens recommended in current treatment guidelines. Results may be sensitive to assumptions about treatment sequencing and the choice and efficacy of subsequent treatment regimens. Copyright The Author(s) 2014

Suggested Citation

  • Josephine Mauskopf & Miny Samuel & Doreen McBride & Usha Mallya & Steven Feldman, 2014. "Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines," PharmacoEconomics, Springer, vol. 32(4), pages 395-409, April.
    • Handle: RePEc:spr:pharme:v:32:y:2014:i:4:p:395-409
    DOI: 10.1007/s40273-014-0130-5
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-014-0130-5
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40273-014-0130-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Laura Sawyer & David Wonderling & Karina Jackson & Ruth Murphy & Eleanor Samarasekera & Catherine Smith, 2015. "Biological Therapies for the Treatment of Severe Psoriasis in Patients with Previous Exposure to Biological Therapy: A Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 33(2), pages 163-177, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:32:y:2014:i:4:p:395-409. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.